Since the efficacy of h145CSA is significantly greater than h145chIgGAA in treating diabetes, we speculate that even if regulatory CD8+ T cells were induced after treatment with either antibody, they may not contribute to the differential efficacy between h145CSA and h145chIgGAA treatments of NOD mice after onset of diabetes. The gene discussed is CD8A; the disease is diabetes mellitus.